This article acknowledges the importance of recent Ebola therapeutics and vaccine breakthroughs but also highlights the importance of infection control, community engagement, and disease surveillance as deciding factors in combating the Ebola crisis in the Democratic Republic of Congo.
Two treatments for Ebola which were undergoing trials in the Democratic Republic of Congo have been stopped early due to their success in treating Ebola. The two treatments will now be made widely available. One of the drugs is REGN-EB3, a cocktail of three monoclonal antibodies developed by Regeneron Pharmaceuticals. The other drug is mAb114, which is now being developed with Ridgeback Biotherapeutics.
The US Army Medical Research Institute of Infectious Diseases (USAMRIID) announced that, for the first time, the US Food and Drug Administration (FDA) has provided formal regulatory agreement for use of an animal model to support development of a drug candidate, remdesivir, for treating deadly Ebola virus infections.
Doctors Without Borders/Médecins Sans Frontières (MSF) will participate in an ongoing randomized controlled trial of four potential Ebola treatments in North Kivu, Democratic Republic of Congo, in collaboration with the Ministry of Health, the international medical humanitarian organization said Tuesday.
Historically, 60–70 percent of patients infected with Ebola virus in central African countries have died.
mAb114 was well tolerated, showed linear pharmacokinetics, and was easily and rapidly infused, making it an attractive and deployable option for treatment in outbreak settings.
In Congo, more than 600 people have contracted the Ebola virus which has claimed close to 400 lives.
The team of scientists demonstrated that a two-antibody cocktail called MBP134 could fully protect nonhuman primates and ferrets against lethal Ebola virus infections of caused by the Bundibugyo and Sudan strain as well as the deadliest Zaire strain.
More than half of the patients who received treatment survived, scientists reported.
Two of the first 16 people to receive an experimental treatment for Ebola have recovered in the current outbreak in North Kivu and Ituri provinces of the Democratic Republic of Congo.